A detailed history of New Edge Advisors, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 4,430 shares of REGN stock, worth $3.42 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
4,430
Previous 4,368 1.42%
Holding current value
$3.42 Million
Previous $4.59 Million 1.44%
% of portfolio
0.03%
Previous 0.03%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1024.09 - $1201.76 $63,493 - $74,509
62 Added 1.42%
4,430 $4.66 Million
Q2 2024

Aug 15, 2024

BUY
$883.2 - $1071.19 $229,632 - $278,509
260 Added 6.33%
4,368 $4.59 Million
Q1 2024

May 14, 2024

SELL
$902.69 - $993.35 $556,959 - $612,896
-617 Reduced 13.06%
4,108 $3.95 Million
Q4 2023

Feb 13, 2024

BUY
$775.18 - $881.7 $1.69 Million - $1.92 Million
2,179 Added 85.59%
4,725 $4.15 Million
Q3 2023

Nov 14, 2023

SELL
$692.45 - $844.37 $711,146 - $867,167
-1,027 Reduced 28.74%
2,546 $2.1 Million
Q2 2023

Aug 14, 2023

SELL
$700.03 - $830.35 $985,642 - $1.17 Million
-1,408 Reduced 28.27%
3,573 $2.57 Million
Q1 2023

May 12, 2023

BUY
$680.49 - $826.97 $654,631 - $795,545
962 Added 23.94%
4,981 $4.09 Million
Q4 2022

Feb 14, 2023

BUY
$705.89 - $766.39 $1.28 Million - $1.39 Million
1,818 Added 82.6%
4,019 $2.9 Million
Q3 2022

Nov 14, 2022

BUY
$573.97 - $724.32 $551,011 - $695,347
960 Added 77.36%
2,201 $1.52 Million
Q2 2022

Aug 09, 2022

BUY
$548.35 - $738.84 $680,502 - $916,900
1,241 New
1,241 $733,000
Q1 2022

May 13, 2022

SELL
$595.12 - $698.43 $903,392 - $1.06 Million
-1,518 Closed
0 $0
Q4 2021

Feb 17, 2022

BUY
$543.48 - $670.97 $471,197 - $581,730
867 Added 133.18%
1,518 $959,000
Q3 2021

Oct 29, 2021

BUY
$574.03 - $680.96 $16,646 - $19,747
29 Added 4.66%
651 $394,000
Q2 2021

Jul 22, 2021

BUY
$472.8 - $558.54 $3,782 - $4,468
8 Added 1.3%
622 $347,000
Q1 2021

Apr 26, 2021

SELL
$446.73 - $548.2 $47,353 - $58,109
-106 Reduced 14.72%
614 $291,000
Q4 2020

Jan 27, 2021

SELL
$478.3 - $607.98 $10,522 - $13,375
-22 Reduced 2.96%
720 $348,000
Q3 2020

Nov 03, 2020

BUY
$544.75 - $658.21 $64,280 - $77,668
118 Added 18.91%
742 $415,000
Q2 2020

Jul 29, 2020

SELL
$493.32 - $643.92 $231,367 - $301,998
-469 Reduced 42.91%
624 $389,000
Q1 2020

May 04, 2020

BUY
$336.18 - $494.43 $159,013 - $233,865
473 Added 76.29%
1,093 $534,000
Q4 2019

Jan 31, 2020

BUY
$274.13 - $376.51 $169,960 - $233,436
620 New
620 $232,000
Q2 2019

Aug 05, 2019

SELL
$299.6 - $414.82 $147,702 - $204,506
-493 Closed
0 $0
Q1 2019

May 14, 2019

SELL
$372.08 - $439.57 $22.1 Million - $26.1 Million
-59,342 Reduced 99.18%
493 $202,000
Q1 2019

May 09, 2019

BUY
$372.08 - $439.57 $22.3 Million - $26.3 Million
59,835 New
59,835 $124,000
Q4 2018

Jan 29, 2019

SELL
$335.82 - $403.04 $396,939 - $476,393
-1,182 Closed
0 $0
Q3 2018

Oct 29, 2018

BUY
$351.14 - $408.51 $415,047 - $482,858
1,182 New
1,182 $478,000
Q4 2017

Feb 08, 2018

SELL
$358.63 - $469.95 $177,163 - $232,155
-494 Closed
0 $0
Q3 2017

Nov 13, 2017

BUY
$431.38 - $504.0 $195,846 - $228,816
454 Added 1135.0%
494 $232,000
Q2 2017

Aug 16, 2017

BUY
N/A
40
40 $0

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $82.9B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.